Evidence map›Paper›PMID 30272263›Full record

ArticleInternational journal of molecular medicine2018

Expression levels of hnRNP K and p21WAF1/CIP1 are associated with resistance to radiochemotherapy independent of p53 pathway activation in rectal adenocarcinoma.

Wassiliki Daskalaki, Eva Wardelmann, Matthias Port, Katharina Stock, Julie Steinestel, Sebastian Huss, Jan Sperveslage, Konrad Steinestel, Stefan Eder

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. RNA-Binding Proteins in Acute Leukemias.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Wassiliki DaskalakiGerhard‑Domagk‑Institute of Pathology, University Hospital Münster, D‑48149 Münster, Germany.
Eva WardelmannGerhard‑Domagk‑Institute of Pathology, University Hospital Münster, D‑48149 Münster, Germany.
Matthias PortBundeswehr Institute of Radiobiology Affiliated to The University of Ulm, D‑80937 Munich, Germany.
Katharina StockGerhard‑Domagk‑Institute of Pathology, University Hospital Münster, D‑48149 Münster, Germany.
Julie SteinestelDepartment of Urology, University Hospital Münster, D‑48149 Münster, Germany.
Sebastian HussGerhard‑Domagk‑Institute of Pathology, University Hospital Münster, D‑48149 Münster, Germany.
Jan SperveslageGerhard‑Domagk‑Institute of Pathology, University Hospital Münster, D‑48149 Münster, Germany.
Konrad SteinestelGerhard‑Domagk‑Institute of Pathology, University Hospital Münster, D‑48149 Münster, Germany.
Stefan EderBundeswehr Institute of Radiobiology Affiliated to The University of Ulm, D‑80937 Munich, Germany.
Universität Ulm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ionizing radiation (IR) is frequently applied in the treatment of rectal adenocarcinoma, however, there is marked variance in the response to radiochemotherapy between individual tumors. In our previous investigations, it was shown that the overexpression of heterogeneous nuclear ribonucleoprotein K (hnRNP K) confers radioresistance to malignant melanoma and colorectal carcinoma (CRC) in vitro, however, the underlying mechanism remains to be elucidated. As hnRNP K, a p53 binding partner and cofactor for the transcriptional activation of p53 target genes, is overexpressed in CRC, the present study investigated the possible radioprotective effect of the hnRNP K/p53‑induced upregulation of p21 (also known as WAF1/CIP1) in rectal adenocarcinoma. Immunohistochemistry was performed for hnRNP K, p53 and p21 in a series of 68 consecutive cases of rectal adenocarcinoma with full molecular characterization following radiochemotherapy and 14 corresponding pre‑therapeutic biopsies, and the results were correlated with clinicopathological characteristics and the percentage of vital tumor cells following therapy. In addition, pathway analyses, protein immunoprecipitation, western immunoblotting and immunofluorescence microscopy were performed to identify dysregulated kinase signaling and hnRNP K targets upon exposure of CRC cells to IR. Although the fraction of vital tumor cells upon neoadjuvant therapy was significantly higher in hnRNP K/p21‑positive tumors (P=0.0047 and P=0.0223, Students' t‑test), no significant association was found between the protein expression levels of hnRNP K, p53 and p21 (P>0.05, χ2 test). Irradiation enhanced apoptotic pathway activation via p53/CHK2 phosphorylation and poly (ADP‑ribose) polymerase cleavage, and induced the overexpression and interaction of hnRNP K and p53. However, p53 Ser15‑phosphorylation was independent of the presence of hnRNP K, and there was no measurable effect of hnRNP K on the expression of p21 in vitro. Taken together, the results of the present study support a radioprotective role for hnRNP K, which may be mediated through an interaction with p53, however, this effect appears to be independent of the hnRNP K/p53‑induced upregulation of p21 in rectal adenocarcinoma.

Indexed as

ChemoradiotherapyAdultAgedAged, 80 and overBlotting, WesternCell Line, TumorColorectal NeoplasmsCyclin-Dependent Kinase Inhibitor p21FemaleGene Expression Regulation, NeoplasticHeterogeneous-Nuclear Ribonucleoprotein KHigh-Throughput Nucleotide SequencingHumansImmunoprecipitationMaleMiddle AgedCyclin-Dependent Kinase Inhibitor p21Heterogeneous-Nuclear Ribonucleoprotein KTumor Suppressor Protein p53

Identifiers

PMID30272263
PMCPMC6202084
OpenAlexW2893794607

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.